IF: 1.578
Cite Score:
1.45
THOMSON REUTERS - SCOPUS

Comparison of Intra-Arterial Chemotherapy with Gemcitabine or Floxuridine Followed by TACE with Oxaliplatine

AUTHORS

Hao Ming Zhi 1 , Chen Qiang 2 , * , Lin Hai Lan 1 , Wu Hui 3 , Chen Qi Zhong 3 , Li Jian Cheng 3 , Zheng Jian Xiong 3 , Ye Yun Bin 3

AUTHORS INFORMATION

1 Department of Interventional Radiology, Fujian Provincial Tumor Hospital, Fujian, P.R.China

2 Department of Medical Oncology, Fujian Provincial Tumor Hospital, cqiang8@pub5.fz.fj.cn, Fujian Province, P.R.China

3 Department of Medical Oncology, Fujian Provincial Tumor Hospital, Fujian Province, P.R.China

How to Cite: Zhi H, Qiang C, Lan L, Hui W, Zhong C, et al. Comparison of Intra-Arterial Chemotherapy with Gemcitabine or Floxuridine Followed by TACE with Oxaliplatine, Hepat Mon. Online ahead of Print ; 9(4):253-260.

ARTICLE INFORMATION

Hepatitis Monthly: 9 (4); 253-260
Article Type: Research Article
Received: July 30, 2009
Accepted: October 12, 2009

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background and Aims: To investigate the efficacy and safety of a gemcitabine plus oxaliplatin combination regimen and a floxuridine plus oxaliplatin combination regimen used in transcatheter arterial chemoembolization for patients with inoperable hepatocellular carcinoma (HCC).

Methods: From October 2005 to October 2008, 122 chemonaïve patients with newly diagnosed, inoperable HCC were randomized into a gemcitabine plus oxaliplatin combination regimen group (GO group) or a floxuridine plus oxaliplatin combination regimen group (FO group). The GO group was treated with 1,600 mg of gemcitabine and 200 mg of oxaliplatin, and the FO group was treated with 1,000 mg of floxuridine and 200 mg of oxaliplatin. Both groups were treated with glutin and iodolipol as the embolic agent in the transcatheter arterial chemoembolization (TACE).

Results: The progression-free survival, the median survival period, and the median time to progress had no significant difference between the two groups. However, there was a significant difference in the incidence of grade 3/4 thrombocytopenia between the two groups (P = 0.002). Grade 3/4 hematologic toxicity was observed only in the GO group. One patient (1.7%) with grade 3/4 leukopenia and 6 patients (10%) with grade 3/4 thrombocytopenia were observed. A multivariate analysis revealed that the Eastern Cooperative Oncology Group (ECOG) scores and portal vein thrombosis were the only independent prognostic factors that affected progression-free survival.

Conclusions: The floxuridine plus oxaliplatin combination regimen was tolerated better than the gemcitabine plus oxaliplatin combination regimen used in TACE.

Keywords

Hepatocellular Carcinoma Transcatheter Arterial Chemoembolization Gemcitabine Floxuridine Oxaliplatin Oxaliplatin Lipiodol Emulsion

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: